A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults

This study compares the safety and immunogenicity profile of combined hepatitis A/B vaccine given alone or concomitantly with MenACWY-CRM to healthy adults.

开始日期2011-10-01

申办/合作机构

GSK Plc

EUCTR2006-003650-20-IT / Not yet recruitingN/A

A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process - ND

开始日期2007-03-26

申办/合作机构

Merck & Co., Inc.

100 项与 Recombinant hepatitis B vaccine(Novartis Vaccines) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant hepatitis B vaccine(Novartis Vaccines) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant hepatitis B vaccine(Novartis Vaccines) 相关的专利（医药）

登录后查看更多信息

项与 Recombinant hepatitis B vaccine(Novartis Vaccines) 相关的文献（医药）

2014-11-01·Expert Review of Vaccines2区 · 医学

Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines

2区 · 医学

Review

作者: Grzegorzewska, Alicja E

The protective immunization rates in response to hepatitis B vaccination in chronic kidney disease (CKD) patients are lower than response rates in the general population because of genetic and CKD-related factors as well as logistic problems with a proper providing of the recommended vaccination schedules. This review focuses on third-generation vaccines and adjuvanted vaccines commercially introduced in some countries, investigated in clinical trials, especially involving CKD patients or used only in the experimental studies. In order to improve the immunization rate, the use of third-generation vaccines (yeast-derived pre-S2/S HBV vaccines, mammalian cell-derived pre-S2/S HBV vaccines, mammalian cell-derived pre-S1/pre-S2/S HBV vaccines), novel adjuvants (AS04, AS02, phosphorothioate oligodeoxyribonucleotide, hemokinin-1, a polysaccharide based on delta inulin, nano-complex Hep-c, cyclic diguanylate) or immunostimulants for enhancement of immunogenicity of existing recombinant hepatitis B vaccines is tried to improve results of hepatitis B vaccination prior to dialysis commencement or already on renal replacement therapy.

100 项与 Recombinant hepatitis B vaccine(Novartis Vaccines) 相关的药物交易

登录后查看更多信息